Analyst Reactions


"The acquisition of Relsys by Oracle strongly demonstrates Oracle's commitment to two major trends driving the industry today, namely the move towards a comprehensive connected eClinical approach to data management and the critical importance of monitoring drug safety both before and after drug approval. Relsys is expected to strengthen Oracle's capabilities by adding a market leading pharmacovigilance solution and new advanced drug safety analytics capabilities to the Oracle Health Sciences industry suite."
Alan Louie Ph.D.
Research Director, IDC Health Industry Insights

Oracle 1-650-633-4490
Toll free in the United States1-800-633-0925
       (Toll Free in the U.S.)